Loading...
Under maintenance — back shortly
HMG-CoA inhibition→reduced hepatic lipogenesis→Wnt/β-catenin suppression
Atorvastatin reduces hepatic lipid accumulation via HMG-CoA reductase inhibition, reducing de novo lipogenesis, and also suppresses the Wnt/β-catenin pathway involved in hepatic fibrosis. Six papers with clinical and preclinical evidence support benefit, with key supportive studies showing curative effect in combination therapy.
“Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients.”
— Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients. (2024)DOI“Atorvastatin appears to inhibit the Wnt/β-catenin signal pathway and achieve good curative effect against nonalcoholic fatty liver disease.”
— The Role of Wnt/beta-Catenin Signal Pathway in the Pathogenesis of Nonalcoholic Fatty Liver Disease and the Effect of Atorvastatin Intervention (2020)DOI“Obtained results showed that resveratrol and atorvastatin combination therapy can improve nonalcoholic fatty liver disease by targeting genes involved in cholesterol metabolism and miR33.”
— Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33. (2023)DOI“In addition, atorvastatin modulated the high-risk PLS in an in vitro model of nonalcoholic fatty liver disease (NAFLD).”
— Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. (2022)DOI“FXR and GPBAR1 maintain intestinal, liver, and cardiovascular homeostasis, and their therapeutic targeting with a dual GPBAR1/FXR ligand and atorvastatin holds potential in the treatment of liver and cardiovascular components of nonalcoholic fatty liver disease.”
— Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease. (2023)DOI“The purpose of this study was to analyze the pathogenesis of nonalcoholic fatty liver disease in rats and study the efficacy of atorvastatin intervention.”
— The Role of Wnt/beta-Catenin Signal Pathway in the Pathogenesis of Nonalcoholic Fatty Liver Disease and the Effect of Atorvastatin Intervention (2020)DOI